One way leads to a future in which AI-driven breakthroughs remain the exclusive domain of pharmaceutical giants with billion-dollar budgets. The other, to a landscape where breakthroughs regularly ...

Just like a fancy camera doesn’t make you a photographer, just having access to powerful AI tools doesn’t mean you’re getting real value out of them. It’s what you do with the tools—how you structure ...

Pollsters, news anchors and newspaper columnists say America is polarized. The day before the 2024 presidential election, The New Yorker released an article titled “The Americans Prepping for a Second ...

A 1966 example of the Ford GT40 MkII is heading to auction in January—and it’s not just any example of the already ultra-rare car, but the “most original” one. Eleven MkII GT40s were built, and just ...

On CNBC's “Mad Money Lightning Round,” on Thursday, Jim Cramer said Recursion Pharmaceuticals (NASDAQ: RXRX) has been “horrendous” and he does not like to recommend horrendous stocks. On the earnings ...

This year, Latin America has taken an unprecedented turn to the right. This political earthquake has been driven by the catastrophe of Venezuela’s Bolivarian Model, Nayib Bukele’s security successes ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

They bayed, they hollered, they hooted, they cheered. After a miserable 18 months, in which they had ranged from dejected to mutinous to feral, Labour mps finally had something to shout for when ...

This is this week’s ForbesWomen newsletter, which every Thursday brings news about the world’s top female entrepreneurs, leaders and investors straight to your inbox. Click here to get on the ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...